Delivra Health Brands (TSXV:DHB) Research & Development: C$0.00 Mil (TTM As of Mar. 2026)


What is Delivra Health Brands Research & Development?

Delivra Health Brands TSXV:DHB Research & Development is C$0.00 Mil as of Mar. 2026. The stock has 3 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. Delivra Health Brands's Research & Development for the three months ended in Mar. 2026 was C$0.00 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 was C$0.00 Mil.

Delivra Health Brands  (TSXV:DHB) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Delivra Health Brands Research & Development Related Terms

Delivra Health Brands Research & Development Historical Data

* Premium members only.

The historical data trend for Delivra Health Brands's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Delivra Health Brands Research & Development Chart

Delivra Health Brands Annual Data
Trend Dec16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.07 0.00 0.00 0.00 0.00

Delivra Health Brands Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Delivra Health Brands Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was C$0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of C$0.00 Mil mean?
Delivra Health Brands (TSXV:DHB) has a Research & Development of C$0.00 Mil as of Mar. 2026. Research and development expense is the total cost for research and development activities. View historical data on Delivra Health Brands and its competitors.
Is Delivra Health Brands' Research & Development too high?
Delivra Health Brands' current Research & Development is C$0.00 Mil.
How does Delivra Health Brands' Research & Development compare to ZTS and UTHR?
Delivra Health Brands' Research & Development of C$0.00 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Drug Manufacturers company?
A good Research & Development depends on the Drug Manufacturers industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Delivra Health Brands and its competitors. Delivra Health Brands's current Research & Development is C$0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Delivra Health Brands stock overvalued right now?
Based on GuruFocus' analysis, Delivra Health Brands (TSXV:DHB) is currently considered Possible Value Trap. The stock's GF Value™ is C$0.25, compared to a current price of C$0.10 — trading 60% below its estimated fair value. The current Research & Development is C$0.00 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Delivra Health Brands (TSXV:DHB), the current Research & Development is C$0.00 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Delivra Health Brands Business Description

Other Exchanges DHBUF:USA3F0:Germany
Address 999 Canada Place, Suite 404, Vancouver, BC, CAN, V6C 3E2
Delivra Health Brands Inc helping people take control of health with alternative wellness solutions. Its portfolio features brands like Dream Water and LivRelief that deliver relief from common, everyday issues like chronic pain, anxiety, and sleeplessness. The principal activities of the company are to provide lifestyle and health and wellness products to consumers and patients in regulated markets. The company geographically operates in Canada and United States, out of which it generates maximum revenue from Unites States.